Does the media refer more to ZBIO or TGTX?

In the previous week, TG Therapeutics had 7 more articles in the media than Zenas BioPharma. MarketBeat recorded 13 mentions for TG Therapeutics and 6 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.86 beat TG Therapeutics' score of 0.62 indicating that Zenas BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, IBRX or ZBIO?

ImmunityBio has higher revenue and earnings than Zenas BioPharma. ImmunityBio is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $165.79M 51.11 -$351.40M -$0.97 N/A Zenas BioPharma $10M 201.57 -$377.74M -$8.99 N/A

Does the media refer more to IBRX or ZBIO?

In the previous week, ImmunityBio had 2 more articles in the media than Zenas BioPharma. MarketBeat recorded 8 mentions for ImmunityBio and 6 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.86 beat ImmunityBio's score of 0.07 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is APGE or ZBIO more profitable?

Apogee Therapeutics' return on equity of -29.88% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Apogee Therapeutics N/A -29.88% -28.08% Zenas BioPharma N/A -122.45% -58.04%

Does the media refer more to APGE or ZBIO?

In the previous week, Apogee Therapeutics and Apogee Therapeutics both had 6 articles in the media. Apogee Therapeutics' average media sentiment score of 1.69 beat Zenas BioPharma's score of 0.86 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMVT or ZBIO more profitable?

Immunovant's return on equity of -69.59% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% Zenas BioPharma N/A -122.45% -58.04%

Does the media refer more to IMVT or ZBIO?

In the previous week, Immunovant and Immunovant both had 6 articles in the media. Immunovant's average media sentiment score of 1.37 beat Zenas BioPharma's score of 0.86 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SYRE or ZBIO more profitable?

Spyre Therapeutics' return on equity of -30.74% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -30.74% -22.23% Zenas BioPharma N/A -122.45% -58.04%

Does the media refer more to SYRE or ZBIO?

In the previous week, Spyre Therapeutics had 11 more articles in the media than Zenas BioPharma. MarketBeat recorded 17 mentions for Spyre Therapeutics and 6 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.86 beat Spyre Therapeutics' score of 0.77 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zenas BioPharma (ZBIO) Competitors

$30.92 -0.99 (-3.09%)

As of 12:23 PM Eastern

Compare

ZBIO vs. TGTX, IBRX, APGE, IMVT, and SYRE

Should you buy Zenas BioPharma stock or one of its competitors? Zenas BioPharma's main competitors and comparable companies include TG Therapeutics (TGTX), ImmunityBio (IBRX), Apogee Therapeutics (APGE), Immunovant (IMVT), and Spyre Therapeutics (SYRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Zenas BioPharma compare to TG Therapeutics?

Zenas BioPharma (NASDAQ:ZBIO) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

TG Therapeutics has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	201.57	-$377.74M	-$8.99	N/A
TG Therapeutics	$616.29M	13.25	$447.18M	$2.74	19.48

58.6% of TG Therapeutics shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by insiders. Comparatively, 8.9% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Zenas BioPharma has a beta of -1.04, meaning that its stock price is 204% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market.

Zenas BioPharma currently has a consensus target price of $45.71, indicating a potential upside of 47.82%. TG Therapeutics has a consensus target price of $63.00, indicating a potential upside of 18.05%. Given Zenas BioPharma's stronger consensus rating and higher possible upside, research analysts plainly believe Zenas BioPharma is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
TG Therapeutics	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

TG Therapeutics has a net margin of 55.22% compared to Zenas BioPharma's net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-122.45%	-58.04%
TG Therapeutics	55.22%	73.49%	34.14%

In the previous week, TG Therapeutics had 7 more articles in the media than Zenas BioPharma. MarketBeat recorded 13 mentions for TG Therapeutics and 6 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.86 beat TG Therapeutics' score of 0.62 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TG Therapeutics beats Zenas BioPharma on 10 of the 16 factors compared between the two stocks.

How does Zenas BioPharma compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Zenas BioPharma (NASDAQ:ZBIO) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

8.6% of ImmunityBio shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ImmunityBio presently has a consensus price target of $14.20, suggesting a potential upside of 77.61%. Zenas BioPharma has a consensus price target of $45.71, suggesting a potential upside of 47.82%. Given ImmunityBio's stronger consensus rating and higher probable upside, research analysts clearly believe ImmunityBio is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Zenas BioPharma has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Zenas BioPharma	N/A	-122.45%	-58.04%

ImmunityBio has higher revenue and earnings than Zenas BioPharma. ImmunityBio is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$165.79M	51.11	-$351.40M	-$0.97	N/A
Zenas BioPharma	$10M	201.57	-$377.74M	-$8.99	N/A

In the previous week, ImmunityBio had 2 more articles in the media than Zenas BioPharma. MarketBeat recorded 8 mentions for ImmunityBio and 6 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.86 beat ImmunityBio's score of 0.07 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Neutral
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmunityBio has a beta of 0.04, indicating that its stock price is 96% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -1.04, indicating that its stock price is 204% less volatile than the broader market.

Summary

ImmunityBio beats Zenas BioPharma on 11 of the 15 factors compared between the two stocks.

How does Zenas BioPharma compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Zenas BioPharma (NASDAQ:ZBIO) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Apogee Therapeutics' return on equity of -29.88% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-29.88%	-28.08%
Zenas BioPharma	N/A	-122.45%	-58.04%

Apogee Therapeutics currently has a consensus price target of $126.77, indicating a potential downside of 6.14%. Zenas BioPharma has a consensus price target of $45.71, indicating a potential upside of 47.82%. Given Zenas BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Zenas BioPharma is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Apogee Therapeutics has higher earnings, but lower revenue than Zenas BioPharma. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A
Zenas BioPharma	$10M	201.57	-$377.74M	-$8.99	N/A

In the previous week, Apogee Therapeutics and Apogee Therapeutics both had 6 articles in the media. Apogee Therapeutics' average media sentiment score of 1.69 beat Zenas BioPharma's score of 0.86 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.0% of Apogee Therapeutics shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Apogee Therapeutics has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -1.04, suggesting that its stock price is 204% less volatile than the broader market.

Summary

Apogee Therapeutics beats Zenas BioPharma on 9 of the 14 factors compared between the two stocks.

How does Zenas BioPharma compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Zenas BioPharma (NASDAQ:ZBIO) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

47.1% of Immunovant shares are held by institutional investors. 1.9% of Immunovant shares are held by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zenas BioPharma has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Zenas BioPharma	$10M	201.57	-$377.74M	-$8.99	N/A

Immunovant presently has a consensus target price of $44.00, suggesting a potential upside of 20.27%. Zenas BioPharma has a consensus target price of $45.71, suggesting a potential upside of 47.82%. Given Zenas BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Zenas BioPharma is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, Immunovant and Immunovant both had 6 articles in the media. Immunovant's average media sentiment score of 1.37 beat Zenas BioPharma's score of 0.86 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -1.04, meaning that its share price is 204% less volatile than the broader market.

Immunovant's return on equity of -69.59% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Zenas BioPharma	N/A	-122.45%	-58.04%

Summary

Zenas BioPharma beats Immunovant on 7 of the 13 factors compared between the two stocks.

How does Zenas BioPharma compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Zenas BioPharma (NASDAQ:ZBIO) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Spyre Therapeutics' return on equity of -30.74% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Zenas BioPharma	N/A	-122.45%	-58.04%

Spyre Therapeutics has higher earnings, but lower revenue than Zenas BioPharma. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	N/A	N/A	-$155.20M	-$1.95	N/A
Zenas BioPharma	$10M	201.57	-$377.74M	-$8.99	N/A

Spyre Therapeutics currently has a consensus target price of $109.69, indicating a potential upside of 21.63%. Zenas BioPharma has a consensus target price of $45.71, indicating a potential upside of 47.82%. Given Zenas BioPharma's higher probable upside, analysts clearly believe Zenas BioPharma is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

80.4% of Spyre Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Spyre Therapeutics had 11 more articles in the media than Zenas BioPharma. MarketBeat recorded 17 mentions for Spyre Therapeutics and 6 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.86 beat Spyre Therapeutics' score of 0.77 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has a beta of 2.99, suggesting that its share price is 199% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -1.04, suggesting that its share price is 204% less volatile than the broader market.

Summary

Spyre Therapeutics beats Zenas BioPharma on 10 of the 15 factors compared between the two stocks.

Get Zenas BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZBIO vs. The Competition

Export

Metric	Zenas BioPharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.02B	$3.84B	$7.17B	$14.37B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-3.44	14.31	273.45	25.33
Price / Sales	201.57	1,541.68	673.36	97.70
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	6.86	15.34	10.44	6.19
Net Income	-$377.74M	-$22.78M	$3.48B	$358.05M
7 Day Performance	-6.43%	-2.47%	-2.04%	-1.55%
1 Month Performance	4.79%	0.33%	-0.24%	-3.54%
1 Year Performance	40.89%	38.57%	18.85%	5.78%

Zenas BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZBIO Zenas BioPharma	2.1275 of 5 stars	$30.93 -3.1%	$45.71 +47.8%	+57.7%	$2.02B	$10M	N/A	167	News Coverage
TGTX TG Therapeutics	3.5818 of 5 stars	$55.74 -0.4%	$63.00 +13.0%	+67.9%	$8.57B	$616.29M	20.34	290	News Coverage Insider Trade
IBRX ImmunityBio	2.0717 of 5 stars	$8.29 +2.6%	$14.20 +71.3%	+221.9%	$8.56B	$165.79M	N/A	590
APGE Apogee Therapeutics	1.5923 of 5 stars	$135.07 flat	$126.77 -6.1%	N/A	$8.40B	N/A	N/A	91	Positive News
IMVT Immunovant	2.8514 of 5 stars	$39.57 +0.8%	$44.00 +11.2%	+133.0%	$8.11B	N/A	N/A	120	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZBIO) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zenas BioPharma (ZBIO) Competitors

ZBIO vs. TGTX, IBRX, APGE, IMVT, and SYRE

How does Zenas BioPharma compare to TG Therapeutics?

Summary

How does Zenas BioPharma compare to ImmunityBio?

Summary

How does Zenas BioPharma compare to Apogee Therapeutics?

Summary

How does Zenas BioPharma compare to Immunovant?

Summary

How does Zenas BioPharma compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBIO vs. The Competition

Zenas BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zenas BioPharma (ZBIO) Competitors

ZBIO vs. TGTX, IBRX, APGE, IMVT, and SYRE

How does Zenas BioPharma compare to TG Therapeutics?

Which has stronger earnings & valuation, ZBIO or TGTX?

Do institutionals & insiders hold more shares of ZBIO or TGTX?

Which has more risk & volatility, ZBIO or TGTX?

Do analysts rate ZBIO or TGTX?

Is ZBIO or TGTX more profitable?

Does the media refer more to ZBIO or TGTX?

Summary

How does Zenas BioPharma compare to ImmunityBio?

Do institutionals and insiders have more ownership in IBRX or ZBIO?

Do analysts recommend IBRX or ZBIO?

Is IBRX or ZBIO more profitable?

Which has stronger valuation and earnings, IBRX or ZBIO?

Does the media refer more to IBRX or ZBIO?

Which has more risk and volatility, IBRX or ZBIO?

Summary

How does Zenas BioPharma compare to Apogee Therapeutics?

Is APGE or ZBIO more profitable?

Do analysts recommend APGE or ZBIO?

Which has preferable earnings & valuation, APGE or ZBIO?

Does the media refer more to APGE or ZBIO?

Do institutionals and insiders believe in APGE or ZBIO?

Which has more risk & volatility, APGE or ZBIO?

Summary

How does Zenas BioPharma compare to Immunovant?

Do institutionals and insiders hold more shares of IMVT or ZBIO?

Which has preferable earnings & valuation, IMVT or ZBIO?

Do analysts recommend IMVT or ZBIO?

Does the media refer more to IMVT or ZBIO?

Which has more risk & volatility, IMVT or ZBIO?

Is IMVT or ZBIO more profitable?

Summary

How does Zenas BioPharma compare to Spyre Therapeutics?

Is SYRE or ZBIO more profitable?

Which has better earnings & valuation, SYRE or ZBIO?

Do analysts rate SYRE or ZBIO?

Do institutionals & insiders have more ownership in SYRE or ZBIO?

Does the media refer more to SYRE or ZBIO?

Which has more risk & volatility, SYRE or ZBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBIO vs. The Competition

Zenas BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools